
Hi All, Thanks for thinking of us! 1) What is the source of these notes from David Chadwick and Karin Smyth? Are these findable on X.com? 2) We have indeed reached out to MHRA and had dialogue about pemivibart in the past, but at least at the time, MHRA had a different view on monoclonal antibodies for COVID than the US FDA, hence we have a US authorization and associated focus. However, things change and so perhaps MHRA thinking has evolved!













